argenx NV ADR (ARGX)vsGyre Therapeutics Inc. (GYRE)
ARGX
argenx NV ADR
$981.33
+0.38%
HEALTHCARE · Cap: $58.31B
GYRE
Gyre Therapeutics Inc.
$4.30
+0.94%
HEALTHCARE · Cap: $470.79M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 5287% more annual revenue ($5.92B vs $109.82M). ARGX leads profitability with a 31.7% profit margin vs -19.3%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
GYRE
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.3%
Fair Value
$2552.01
Current Price
$981.33
$1570.68 discount
Intrinsic value data unavailable for GYRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Safe zone — low bankruptcy risk
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 182.4x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.3% — below average capital efficiency
Revenue declined 2.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while GYRE is a turnaround play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 25/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?